Drug-induced endocrine and metabolic disorders

Drug Safety

Volumn 30, Issue 3, 2007, Pages 215-245

  Ma, Ronald C W ^a,d   Kong, Alice P S ^a,b   Chan, Norman ^c   Tong, Peter C Y ^a   Chan, Juliana C N ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^c Qualigenics Diabetes Centre   (Hong Kong)

^d CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; ADRENERGIC RECEPTOR STIMULATING AGENT; AMIODARONE; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISPHOSPHONIC ACID DERIVATIVE; CATECHOLAMINE; CHINESE DRUG; CORTICOSTEROID; ENDOCRINE DISRUPTOR; FATTY ACID; GAMMA INTERFERON; GLUCAGON; INSULIN; LEVOTHYROXINE SODIUM; LITHIUM; NEUROLEPTIC AGENT; NORADRENALIN; ORAL CONTRACEPTIVE AGENT; PENTAMIDINE; PROTEINASE INHIBITOR; SULFONYLUREA; THIONAMIDE DERIVATIVE; THYROXINE DERIVATIVE; TOXIN; UNINDEXED DRUG;

ADRENAL INSUFFICIENCY; ARTHRALGIA; CALCIUM BALANCE; CLINICAL TRIAL; DIABETES MELLITUS; DIAGNOSTIC PROCEDURE; DIFFERENTIAL DIAGNOSIS; DISORDERS OF CARBOHYDRATE METABOLISM; DRUG INDUCED DISEASE; DRUG POTENTIATION; DYSLIPIDEMIA; ELECTROLYTE BALANCE; ELECTROLYTE DISTURBANCE; ENDOCRINE DISEASE; FLU LIKE SYNDROME; FOOD INTAKE; GLUCOSE METABOLISM; GOITER; GONAD DYSFUNCTION; GONADOTROPIN RELEASE; GYNECOMASTIA; HERBAL MEDICINE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMEOSTASIS; HUMAN; HYPERCALCEMIA; HYPERCHOLESTEROLEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERNATREMIA; HYPERPROLACTINEMIA; HYPERTHYROIDISM; HYPERTRIGLYCERIDEMIA; HYPOCALCEMIA; HYPOGLYCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHYSIS GONAD SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; HYPOTHYROIDISM; INSULIN RELEASE; INSULIN RESISTANCE; LIPOATROPHY; LIPODYSTROPHY; LIPOHYPERTROPHY; METABOLIC DISORDER; METABOLIC SYNDROME X; OBESITY; OSTEOPOROSIS; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SEXUAL DYSFUNCTION; SIDE EFFECT; THYROID DISEASE; VIRILIZATION; VITAMIN D DEFICIENCY; WEIGHT GAIN;

EID: 33947266378     PISSN: 01145916     EISSN: None     Source Type: Journal    
DOI: 10.2165/00002018-200730030-00005     Document Type: Review

References (279)

1. Cavaghan ML, Polonsky KS. Insulin secretion in vivo. In: Kahn CR, Weir GC, King GL, editors. Joslin's diabetes mellitus. Boston (MA): Lippincott Williams and Wilkins, 2005: 109-24
2. Henquin JC. Pathways in beta-cell stimulus-secretion coupling as targets for therapeutic insulin secretagogues. Diabetes 2004; 53 Suppl. 3: S48-58
3. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284 (4): E671-8
4. Axelrod J, Reisine TD. Stress hormones: their interaction and regulation. Science 1984; 224 (4648): 452-9
5. Stalmans W, Laloux M. Glucocorticoids and hepatic glycogen metabolism. Monogr Endocrinol 1979; 12: 517-33
6. Randle PJ, Garland PB, Hales CN, et al. The glucose fatty-acid cycle: its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet 1963; I: 785-9
7. McGarry JD. Banting lecture 2001: dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 2002; 51 (1): 7-18
8. Boden G, Chen X, Ruiz J, et al. Mechanisms of fatty acid-induced inhibition of glucose uptake. J Clin Invest 1994; 93 (6): 2438-46
9. Krssak M, Falk Petersen K, Dresner A, et al. Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans: a 1H NMR spectroscopy study. Diabetologia 1999; 42 (1): 113-6
10. Dresner A, Laurent D, Marcucci M, et al. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 1999; 103 (2): 253-9
11. Ferre P. The biology of peroxisome proliferator-activated receptors: relationship with lipid metabolism and insulin sensitivity. Diabetes 2004; 53 Suppl. 1: S43-50
12. Deeb SS, Zambon A, Carr MC, et al. Hepatic lipase and dyslipidemia: interactions among genetic variants, obesity, gender, and diet. J Lipid Res 2003; 44 (7): 1279-86
13. Brindley DN. Role of glucocorticoids and fatty acids in the impairment of lipid metabolism observed in the metabolic syndrome. Int J Obes Relat Metab Disord 1995; 19 Suppl. 1: S69-75
14. Holst JJ. Glucagon-like peptide-1: from extract to agent. The Claude Bernard Lecture, 2005. Diabetologia 2006; 49 (2): 253-60
15. Ahren B. Autonomic regulation of islet hormone secretion: implications for health and disease. Diabetologia 2000 Apr; 43 (4): 393-410
16. Saladin R, De Vos P, Guerre-Millo M, et al. Transient increase in obese gene expression after food intake or insulin administration. Nature 1995; 377 (6549): 527-9
17. Seals DR, Bell C. Chronic sympathetic activation: consequence and cause of age-associated obesity? Diabetes 2004; 53 (2): 276-84
18. Bruning JC, Gautam D, Burks DJ, et al. Role of brain insulin receptor in control of body weight and reproduction. Science 2000; 289 (5487): 2122-5
19. Chehab FF. A broader role for leptin. Nat Med 1996; 2 (7): 723-4
20. Schwartz MW, Woods SC, Porte D, et al. Central nervous system control of food intake. Nature 2000; 404 (6778): 661-71
21. Diagnosis and classification of diabetes mellitus. Diabetes Care 2006; 29 Suppl 1: S43-8
22. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005; 112 (17): 2735-52
23. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366 (9491): 1059-62
24. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365 (9468): 1415-28
25. Emmer M, Gorden P, Roth J. Diabetes in association with other endocrine disorders. Med Clin North Am 1971 Jul; 55 (4): 1057-64
26. Bjorntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev 2001; 2 (2): 73-86
27. Lee ZS, Chan JC, Yeung VT, et al. Plasma insulin, growth hormone, cortisol, and central obesity among young Chinese type 2 diabetic patients. Diabetes Care 1999; 22 (9): 1450-7
28. Lee ZS, Critchley JA, Tomlinson B, et al. Urinary epinephrine and norepinephrine interrelations with obesity, insulin, and the metabolic syndrome in Hong Kong Chinese. Metabolism 2001; 50 (2): 135-43
29. Tong PC, Ho CS, Yeung VT, et al. Association of testosterone, insulin-like growth factor-I, and C-reactive protein with metabolic syndrome in Chinese middle-aged men with a family history of type 2 diabetes. J Clin Endocrinol Metab 2005; 90 (12): 6418-23
30. Pandit MK, Burke J, Gustafson AB, et al. Drug-induced disorders of glucose intolerance. Ann Intern Med 1993 Apr 1; 118 (7): 529-39
31. Sholter DE, Armstrong PW. Adverse effects of corticosteroids on the cardiovascular system. Can J Cardiol 2000; 16 (4): 505-11
32. Leaming RD, Prince MJ. Endocrine and pharmacologic causes of insulin resistance. In: Chrousos GP, Olefsky JM, Samols E, editors. Hormone resistance and hypersensitivity states. Philadelphia (PA): Lippincott Williams and Wilkins, 2002
33. Yudkin JS. Factors influencing threshold and choice of treatment for hypertension in NIDDM: cardiovascular factors. Diabetes Care 1991; 14 Suppl. 4: 27-32
34. Gress TW, Nieto FJ, Shahar E, et al. Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus: atherosclerosis Risk in Communities Study. N Engl J Med 2000; 342 (13): 905-12
35. Dahlof B, Sever PS, Poulter NR, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005; 366 (9489): 895-906
36. Fonseca V, Phear DN. Hyperosmolar non-ketotic diabetic syndrome precipitated by treatment with diuretics. BMJ (Clin Res Ed) 1982; 284 (6308): 36-7
37. Hall S. Hyperosmolar non-ketotic diabetic syndrome precipitated by treatment with diuretics. BMJ (Clin Res Ed) 1982; 284 (6316): 665-6
38. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32 (2): 106-11
39. Neutel JM. Metabolic manifestations of low-dose diuretics. Am J Med 1996; 101 (3A): 71S-82S
40. Jacob S, Rett K, Henriksen EJ. Antihypertensive therapy and insulin sensitivity: do we have to redefine the role of beta-blocking agents? Am J Hypertens 1998; 11 (10): 1258-65
41. Preuss HG, Burris JF. Adverse metabolic effects of antihypertensive drugs: implications for treatment. Drug Saf 1996; 14 (6): 355-64
42. Bell DS. Advantages of a third-generation beta-blocker in patients with diabetes mellitus. Am J Cardiol 2004; 93 (9A): 49B-52B
43. Weir MR, Moser M. Diuretics and beta-blockers: is there a risk for dyslipidemia? Am Heart J 2000; 139 (1 Pt 1): 174-83
44. Leren P. Effects of oral antihypertensive agents on blood lipid levels. Clin Ther 1986; 8 (3): 309-19
45. Freis ED. The cardiotoxicity of thiazide diuretics: review of the evidence. J Hypertens Suppl 1990; 8 (2): S23-32
46. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288 (23): 2981-97
47. Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003; 289 (19): 2560-72
48. Zillich AJ, Garg J, Basu S, et al. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension 2006; 48 (2): 219-24
49. Helderman JH, Elahi D, Andersen DK, et al. Prevention of the glucose intolerance of thiazide diuretics by maintenance of body potassium. Diabetes 1983; 32: 106-11
50. Rabkin SW. Mechanisms of action of adrenergic receptor blockers on lipids during antihypertensive drug treatment. J Clin Pharmacol 1993; 33 (3): 286-91
51. Weidmann P, Gerber A. Effects of treatment with diuretics on serum lipoproteins. J Cardiovasc Pharmacol 1984; 6 Suppl. 1: S260-8
52. Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg 1986; 10 (4): 586-92
53. Bernal-Mizrachi C, Weng S, Feng C, et al. Dexamethasone induction of hypertension and diabetes is PPAR-alpha dependent in LDL receptor-null mice. Nat Med 2003; 9 (8): 1069-75
54. Vidal-Puig AJ, Considine RV, Jimenez-Linan M, et al. Peroxisome proliferator-activated receptor gene expression in human tissues: effects of obesity, weight loss, and regulation by insulin and glucocorticoids. J Clin Invest 1997; 99 (10): 2416-22
55. Ettinger WH Jr, Hazzard WR. Prednisone increases very low density lipoprotein and high density lipoprotein in healthy men. Metabolism 1988 Nov; 37 (11): 1055-8
56. Trence DL. Management of patients on chronic glucocorticoid therapy: an endocrine perspective. Prim Care 2003; 30 (3): 593-605
57. Harvengt C. Effect of oral contraceptive use on the incidence of impaired glucose tolerance and diabetes mellitus. Diabetes Metab 1992; 18 (2): 71-7
58. Henkin Y, Como JA, Oberman A. Secondary dyslipidemia: inadvertent effects of drugs in clinical practice. JAMA 1992; 267 (7): 961-8
59. Lipson A, Stoy DB, LaRosa JC, et al. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception 1986 Aug; 34 (2): 121-34
60. Seibert C, Barbouche E, Fagan J, et al. Prescribing oral contraceptives for women older than 35 years of age. Ann Intern Med 2003; 138 (1): 54-64
61. LaRosa JC. Effects of oral contraceptives on circulating lipids and lipoproteins: maximizing benefit, minimizing risk. Int J Fertil 1989; 34 Suppl.: 71-84
62. Ryan MC, Collins P, Thakore JH. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am J Psychiatry 2003; 160 (2): 284-9
63. Arneson GA. Phenothiazine derivatives and glucose metabolism. J Neuropsychiatr 1964; 5: 181-5
64. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001; 62 Suppl. 27: 15-26; discussion 40-1
65. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27 (2): 596-601
66. Luna B, Feinglos MN. Drug-induced hyperglycemia. JAMA 2001; 286 (16): 1945-8
67. Koval MS, Rames LJ, Christie S. Diabetic ketoacidosis associated with clozapine treatment. Am J Psychiatry 1994; 151 (10): 1520-1
68. Kamran A, Doraiswamy PM, Jane JL, et al. Severe hyperglycemia associated with high doses of clozapine. Am J Psychiatry 1994; 151 (9): 1395
69. Sernyak MJ, Gulanski B, Leslie DL, et al. Undiagnosed hyperglycemia in clozapine-treated patients with schizophrenia. J Clin Psychiatry 2003; 64 (5): 605-8
70. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000; 157 (6): 975-81
71. Henderson DC, Nguyen DD, Copeland PM, et al. Clozapine, diabetes mellitus, hyperlipidemia, and cardiovascular risks and mortality: results of a 10-year naturalistic study. J Clin Psychiatry 2005; 66 (9): 1116-21
72. Koller E, Schneider B, Bennett K, et al. Clozapine-associated diabetes. Am J Med 2001; 111 (9): 716-23
73. Bonanno DG, Davydov L, Botts SR. Olanzapine-induced diabetes mellitus. Ann Pharmacother 2001; 35 (5): 563-5
74. Wirshing DA, Pierre JM, Eyeler J, et al. Risperidone-associated new-onset diabetes. Biol Psychiatry 2001; 50 (2): 148-9
75. Smith RC, Lindenmayer JP, Bark N, et al. Clozapine, risperidone, olanzapine, and conventional antipsychotic drug effects on glucose, lipids, and leptin in schizophrenic patients. Int J Neuropsychopharmacol 2005; 8 (2): 183-94
76. Sumiyoshi T, Roy A, Anil AE, et al. A comparison of incidence of diabetes mellitus between atypical antipsychotic drugs: a survey for clozapine, risperidone, olanzapine, and quetiapine. J Clin Psychopharmacol 2004; 24 (3): 345-8
77. Moisan J, Gregoire JP, Gaudet M, et al. Exploring the risk of diabetes mellitus and dyslipidemia among ambulatory users of atypical antipsychotics: a population-based comparison of risperidone and olanzapine. Pharmacoepidemiol Drug Saf 2005; 14 (6): 427-36
78. Caro JJ, Ward A, Levinton C, et al. The risk of diabetes during olanzapine use compared with risperidone use: a retrospective database analysis. J Clin Psychiatry 2002; 63 (12): 1135-9
79. Bettinger TL, Mendelson SC, Dorson PG, et al. Olanzapine-induced glucose dysregulation. Ann Pharmacother 2000; 34 (7-8): 865-7
80. Crum NF, Riffenburgh RH, Wegner S, et al. Comparisons of causes of death and mortality rates amoung HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr 2006 Feb 1; 24 (2): 194-200
81. Hardy H, Esch LD, Morse GD. Glucose disorders associated with HIV and its drug therapy. Ann Pharmacother 2001; 35 (3): 343-51
82. Tsiodras S, Mantzoros C, Hammer S, et al. Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy: a 5-year cohort study. Arch Intern Med 2000; 160 (13): 2050-6
83. Mulligan K, Grunfeld C, Tai VW, et al. Hyperlipidemia and insulin resistance are induced by protease inhibitors independent of changes in body composition in patients with HIV infection. J Acquir Immune Defic Syndr 2000; 23 (1): 35-43
84. Carr A, Samaras K, Thorisdottir A, et al. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: a cohort study. Lancet 1999; 353 (9170): 2093-9
85. Walli R, Herfort O, Michl GM, et al. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients. AIDS 1998; 12 (15): F167-73
86. Yarasheski KE, Tebas P, Sigmund C, et al. Insulin resistance in HIV protease inhibitor-associated diabetes. J Acquir Immune Defic Syndr 1999; 21 (3): 209-16
87. Unger RH. Minireview: weapons of lean body mass destruction: the role of ectopic lipids in the metabolic syndrome. Endocrinology 2003; 144 (12): 5159-65
88. Hadigan C. Diabetes, insulin resistance, and HIV. Curr Infect Dis Rep 2006; 8 (1): 69-75
89. Schambelan M, Benson CA, Carr A, et al. Management of metabolic complications associated with antiretroviral therapy for HIV-1 infection: recommendations of an International AIDS Society-USA panel. J Acquir Immune Defic Syndr 2002; 31 (3): 257-75
90. Chan JC, Cockram CS, Critchley JA. Drug-induced disorders of glucose metabolism. Mechanisms and management. Drug Saf 1996; 15 (2): 135-57
91. Moore GL, McBurney PL, Service FJ. Self-induced hypoglycemia: a review of psychiatric aspects and report of three cases. Int J Psychiatry Med 1973; 4 (3): 301-11
92. Gordon MR, Flockhart D, Zawadzki JK, et al. Hypoglycemia due to inadvertent dispensing of chlorpropamide. Am J Med 1988; 85 (2): 271-2
93. Shumak SL, Corenblum B, Steiner G. Recurrent hypoglycemia secondary to drug-dispensing error. Arch Intern Med 1991; 151 (9): 1877-8
94. Moore DF, Wood DF, Volans GN. Features, prevention and management of acute overdose due to antidiabetic drugs. Drug Saf 1993; 9 (3): 218-29
95. Service FJ. Diagnostic approach to adults with hypoglycemic disorders. Endocrinol Metab Clin North Am 1999; 28 (3): 519-32, vi
96. Schattner A, Rimon E, Green L, et al. Hypoglycemia induced by co-trimoxazole in AIDS. BMJ 1988; 297 (6650): 742
97. Johnson JA, Kappel JE, Sharif MN. Hypoglycemia secondary to trimethoprim/sulfamethoxazole administration in a renal transplant patient. Ann Pharmacother 1993; 27 (3): 304-6
98. Mathews WA, Manint JE, Kleiss J. Trimethoprim-sulfamethoxazole-induced hypoglycemia as a cause of altered mental status in an elderly patient. J Am Board Fam Pract 2000; 13 (3): 211-2
99. Shah JH, DeLeon-Jones FA, Schickler R, et al. Symptomatic reactive hypoglycemia during glucose tolerance test in lithium-treated patients. Metabolism 1986; 35 (7): 634-9
100. Hunt NJ. Hypoglycemic effect of lithium. Biol Psychiatry 1987; 22 (6): 798-9
101. Smith RC, Sullivan M, Geller J. Inadequate adrenergic response to disopyramide-induced hypoglycemia. Ann Pharmacother 1992; 26 (4): 490-1
102. Croxson MS, Shaw DW, Henley PG, et al. Disopyramide-induced hypoglycaemia and increased serum insulin. N Z Med J 1987; 100 (827): 407-8
103. Cacoub P, Deray G, Baumelou A, et al. Disopyramide-induced hypoglycemia: case report and review of the literature. Fundam Clin Pharmacol 1989; 3 (5): 527-35
104. Strathman I, Schubert EN, Cohen A, et al. Hypoglycemia in patients receiving disopyramide phosphate. Drug Intell Clin Pharm 1983; 17 (9): 635-8
105. Reynolds RM, Walker JD. Hypoglycaemia induced by disopyramide in a patient with type 2 diabetes mellitus. Diabet Med 2001; 18 (12): 1009-10
106. Bertrand G, Gross R, Petit P, et al. Evidence for a direct stimulatory effect of cibenzoline on insulin secretion in rats. Eur J Pharmacol 1992; 214 (2-3): 159-63
107. Jeandel C, Preiss MA, Pierson H. Hypoglycaemia induced by cibenzoline. Lancet 1988; I: 1532-3
108. Gachot BA, Bezier M, Cherrier JF, et al. Cibenzoline and hypoglycaemia. Lancet 1988; 2 (8605): 280
109. Bichel T, Canivet JL, Damas P, et al. Malignant hyperthermia and severe hypoglycemia after reexposure to halothane. Acta Anaesthesiol Belg 1994; 45 (1): 23-7
110. Rowland MJ, Bransome ED Jr, Hendry LB. Hypoglycemia caused by selegiline, an antiparkinsonian drug: can such side effects be predicted? J Clin Pharmacol 1994; 34 (1): 80-5
111. Singh B, Gupta S, Minocha SK, et al. Hypoglycaemia in aluminium phosphide poisoning. J Assoc Physicians India 1994; 42 (8): 663
112. Isotani H, Kameoka K. Hypoglycemia associated with maprotiline in a patient with type 1 diabetes. Diabetes Care 1999; 22 (5): 862-3
113. Zogno MG, Tolfo L, Draghi E. Hypoglycemia caused by maprotiline in a patient taking oral antidiabetics. Ann Pharmacother 1994; 28 (3): 406
114. Otsuka M, Akiba T, Okita Y, et al. Lactic acidosis with hypoglycemia and hyperammonemia observed in two uremic patients during calcium hopantenate treatment. Jpn J Med 1990; 29 (3): 324-8
115. Wong ST, Ng WY, Thai AC. Case report: autoimmune insulin syndrome in a Chinese female with Graves' disease. Ann Acad Med Singapore 1996; 25 (6): 882-5
116. Wiederholt IC, Genco M, Foley JM. Recurrent episodes of hypoglycemia induced by propoxyphene. Neurology 1967; 17 (7): 703-6
117. Florez LR, Rozanski J, Castro A, et al. Propoxyphene-induced hypoglycemia. J Fla Med Assoc 1977; 64 (3): 163-4
118. Service FJ. Hypoglycemic disorders. N Engl J Med 1995; 332 (17): 1144-52
119. Ma RC, Tong PC, Chan JC, et al. A 67-year-old woman with recurrent hypoglycemia: non-islet cell tumour hypoglycemia. CMAJ 2005; 173 (4): 359-61
120. Hypoglycemia in the Diabetes Control and Complications Trial. The Diabetes Control and Complications Trial Research Group. Diabetes 1997; 46 (2): 271-86
121. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998; 352 (9131): 837-53
122. Maran A, Lomas J, Macdonald IA, et al. Lack of preservation of higher brain function during hypoglycaemia in patients with intensively-treated IDDM. Diabetologia 1995; 38 (12): 1412-8
123. Amiel SA, Tamborlane WV, Simonson DC, et al. Defective glucose counterregulation after strict glycemic control of insulin-dependent diabetes mellitus. N Engl J Med 1987; 316 (22): 1376-83
124. Boyle PJ, Kempers SF, O'Connor AM, et al. Brain glucose uptake and unawareness of hypoglycemia in patients with insulin-dependent diabetes mellitus. N Engl J Med 1995; 333 (26): 1726-31
125. Epidemiology of severe hypoglycemia in the diabetes control and complications trial. The DCCT Research Group. Am J Med 1991; 90 (4): 450-9
126. Cryer PE. Hypoglycemia: pathophysiology, diagnosis, and treatment. New York: Oxford University Press, 1997
127. Fanelli CG, Epifano L, Rambotti AM, et al. Meticulous prevention of hypoglycemia normalizes the glycemic thresholds and magnitude of most of neuroendocrine responses to, symptoms of, and cognitive function during hypoglycemia in intensively treated patients with short-term IDDM. Diabetes 1993; 42 (11): 1683-9
128. Amiel SA. Human insulin in hypoglycemia: a new arena? Diabetes 1995; 44 (3): 257-60
129. Anderson JH, Brunelle RL, Koivisto VA, et al. Reduction of postprandial hyperglycemia and frequency of hypoglycemia in IDDM patients on insulin-analog treatment. Multicenter Insulin Lispro Study Group. Diabetes 1997; 46 (2): 265-70
130. Holleman F, Schmitt H, Rottiers R, et al. Reduced frequency of severe hypoglycemia and coma in well-controlled IDDM patients treated with insulin lispro. The Benelux-UK Insulin Lispro Study Group. Diabetes Care 1997; 20 (12): 1827-32
131. Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003; 25 (6): 1541-77, discussion 1539-40
132. Ashwell SG, Amiel SA, Bilous RW, et al. Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with type 1 diabetes. Diabet Med 2006; 23 (3): 285-92
133. Richardson T, Kerr D. Skin-related complications of insulin therapy: epidemiology and emerging management strategies. Am J Clin Dermatol 2003; 4 (10): 661-7
134. Jackson JE, Bressler R. Clinical pharmacology of sulphonylurea hypoglycaemic agents: part 2. Drugs 1981; 22 (4): 295-320
135. Chan TY. Anti-diabetic drugs as a cause of hypoglycaemia among acute medical admissions in Hong Kong and Singapore - relationship to the prescribing patterns in diabetic patients. Singapore Med J 1998; 39 (4): 186-8
136. Goldberg RB, Einhorn D, Lucas CP, et al. A randomized placebo-controlled trial of repaglinide in the treatment of type 2 diabetes. Diabetes Care 1998; 21 (11): 1897-903
137. Malaisse WJ. Pharmacology of the meglitinide analogs: new treatment options for type 2 diabetes mellitus. Treat Endocrinol 2003; 2 (6): 401-14
138. Rosenstock J, Hassman DR, Madder RD, et al. Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 2004; 27 (6): 1265-70
139. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents: an update. Drug Saf 2005; 28 (7): 601-31
140. van de Wiel A. Diabetes mellitus and alcohol. Diabetes Metab Res Rev 2004; 20 (4): 263-7
141. Kajosaari LI, Niemi M, Neuvonen M, et al. Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005; 78 (4): 388-99
142. Hatorp V, Hansen KT, Thomsen MS. Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide. J Clin Pharmacol 2003; 43 (6): 649-60
143. Scheen AJ. Renin-angiotensin system inhibition prevents type 2 diabetes mellitus: part 1. A meta-analysis of randomised clinical trials. Diabetes Metab 2004; 30 (6): 487-96
144. Scheen AJ. Prevention of type 2 diabetes mellitus through inhibition of the renin-angiotensin system. Drugs 2004; 64 (22): 2537-65
145. Kjeldsen SE, Lyle PA, Tershakovec AM, et al. Targeting the renin-angiotensin system for the reduction of cardiovascular outcomes in hypertension: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers. Expert Opin Emerg Drugs 2005; 10 (4): 729-45
146. Leung PS, Carlsson PO. Pancreatic islet renin angiotensin system: its novel roles in islet function and in diabetes mellitus. Pancreas 2005; 30 (4): 293-8
147. Schupp M, Janke J, Clasen R, et al. Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-gamma activity. Circulation 2004; 109 (17): 2054-7
148. Miura Y, Yamamoto N, Tsunekawa S, et al. Replacement of valsartan and candesartan by telmisartan in hypertensive patients with type 2 diabetes: metabolic and antiatherogenic consequences. Diabetes Care 2005; 28 (3): 757-8
149. Holm G, Herlitz J, Smith U. Severe hypoglycaemia during physical exercise and treatment with beta-blockers. BMJ (Clin Res Ed) 1981; 282 (6273): 1360
150. Brown DR, Brown MJ. Hypoglycemia associated with preoperative metoprolol administration. Anesth Analg 2004; 99 (5): 1427-8
151. Brazy JE, Pupkin MJ. Effects of maternal isoxsuprine administration on preterm infants. J Pediatr 1979; 94 (3): 444-8
152. Musci MN Jr, Abbasi S, Otis C, et al. Prolonged fetal ritodrine exposure and immediate neonatal outcome. J Perinatol 1988; 8 (1): 27-32
153. Epstein MF, Nicholls E, Stubblefield PG. Neonatal hypoglycemia after beta-sympathomimetic tocolytic therapy. J Pediatr 1979; 94 (3): 449-53
154. Ozdemir D, Yilmaz E, Duman M, et al. Hypoglycemia after albuterol overdose in a pediatric patient. Pediatr Emerg Care 2004; 20 (7): 464-5
155. Wasserman D, Amitai Y. Hypoglycemia following albuterol overdose in a child. Am J Emerg Med 1992; 10 (6): 556-7
156. Okitolonda W, Delacollette C, Malengreau M, et al. High incidence of hypoglycaemia in African patients treated with intravenous quinine for severe malaria. BMJ (Clin Res Ed) 1987; 295 (6600): 716-8
157. Davis TM, Pukrittayakamee S, Supanaranond W, et al. Glucose metabolism in quinine-treated patients with uncomplicated falciparum malaria. Clin Endocrinol (Oxf) 1990; 33 (6): 739-49
158. Fairhurst RM, Sadou B, Guindo A, et al. Case report: life-threatening hypoglycaemia associated with sulfadoxine-pyrimethamine, a commonly used antimalarial drug. Trans R Soc Trop Med Hyg 2003; 97 (5): 595-6
159. Shojania K, Koehler BE, Elliott T. Hypoglycemia induced by hydroxychloroquine in a type II diabetic treated for polyarthritis. J Rheumatol 1999; 26 (1): 195-6
160. Abu-Shakra M, Lee P. Hypoglycemia: an unusual adverse reaction to chloroquine. Clin Exp Rheumatol 1994; 12 (1): 95
161. Goyal V, Bordia A. The hypoglycemic effect of chloroquine. J Assoc Physicians India 1995; 43 (1): 17-8
162. Taylor TE, Molyneux ME, Wirima JJ, et al. Blood glucose levels in Malawian children before and during the administration of intravenous quinine for severe falciparum malaria. N Engl J Med 1988; 319 (16): 1040-7
163. Foisy MM, Slayter KL, Hewitt RG, et al. Pancreatitis during intravenous pentamidine therapy in an AIDS patient with prior exposure to didanosine. Ann Pharmacother 1994; 28 (9): 1025-8
164. Pais JR, Cazorla C, Novo E, et al. Massive haemorrhage from rupture of a pancreatic pseudocyst after pentamidine-associated pancreatitis. Eur J Med 1992; 1 (4): 251-3
165. Villamil A, Hammer RA, Rodriguez FH. Edematous pancreatitis associated with intravenous pentamidine. South Med J 1991; 84 (6): 796-8
166. Perronne C, Bricaire F, Leport C, et al. Hypoglycaemia and diabetes mellitus following parenteral pentamidine mesylate treatment in AIDS patients. Diabet Med 1990; 7 (7): 585-9
167. Bouchard P, Sai P, Reach G, et al. Diabetes mellitus following pentamidine-induced hypoglycemia in humans. Diabetes 1982; 31 (1): 40-5
168. Sattler FR, Waskin H. Pentamidine and fatal hypoglycemia. Ann Intern Med 1987; 107 (5): 789-90
169. Stahl-Bayliss CM, Kalman CM, Laskin OL. Pentamidine-induced hypoglycemia in patients with the acquired immune deficiency syndrome. Clin Pharmacol Ther 1986; 39 (3): 271-5
170. Spadafora MP, Roberts JR. Hypoglycemic coma from pentamadine in an AIDS patient. Am J Emerg Med 1986; 4 (4): 384
171. Assan R, Perronne C, Assan D, et al. Pentamidine-induced derangements of glucose homeostasis. Determinant roles of renal failure and drug accumulation. A study of 128 patients. Diabetes Care 1995; 18 (1): 47-55
172. Waskin H, Stehr-Green JK, Helmick CG, et al. Risk factors for hypoglycemia associated with pentamidine therapy for Pneumocystis pneumonia. Jama 1988; 260 (3): 345-7
173. Comtois R, Pouliot J, Gervais A, et al. High pentamidine levels associated with hypoglycemia and azotemia in a patient with Pneumocystis carinii pneumonia. Diagn Microbiol Infect Dis 1992; 15 (6): 523-6
174. Karboski JA, Godley PJ. Inhaled pentamidine and hypoglycemia. Ann Intern Med 1988; 108 (3): 490
175. Henriksen JH, Moller S. Liver cirrhosis and arterial hypertension. World J Gastroenterol 2006; 12 (5): 678-85
176. Robertson GL. Antidiuretic hormone. Normal and disordered function. Endocrinol Metab Clin North Am 2001 Sep; 30 (3): 671-94
177. Chan TY. Indapamide-induced severe hyponatremia and hypokalemia. Ann Pharmacother 1995; 29 (11): 1124-8
178. Chapman MD, Hanrahan R, McEwen J, et al. Hyponatraemia and hypokalaemia due to indapamide. Med J Aust 2002; 176 (5): 219-21
179. Chow KM, Szeto CC, Wong TY, et al. Risk factors for thiazide-induced hyponatraemia. QJM 2003; 96 (12): 911-7
180. Chow KM, Kwan BC, Szeto CC. Clinical studies of thiazide-induced hyponatremia. J Natl Med Assoc 2004; 96 (10): 1305-8
181. Friedman E, Shadel M, Halkin H, et al. Thiazide-induced hyponatremia: reproducibility by single dose rechallenge and an analysis of pathogenesis. Ann Intern Med 1989; 110 (1): 24-30
182. Rose BD. Diuretics. Kidney Int 1991 Feb; 39 (2): 336-52
183. Henry RC. Weight reduction pills. JAMA 1967; 201 (11): 895-6
184. Kruger J, Galuska DA, Serdula MK, et al. Attempting to lose weight: specific practices among U.S. adults. Am J Prev Med 2004; 26 (5): 402-6
185. Stewart PM. Mineralcorticoid hypertension. Lancet 1999 Apr 17; 353 (9161): 1341-7
186. Funder JW. 11 beta-Hydroxysteroid dehydrogenase: new answers, new questions. Eur J Endocrinol 1996 Mar; 134 (3): 301-7
187. Clausen T, Flatman JA. Effects of insulin and epinephrine on Na+-K+ and glucose transport in soleus muscle. Am J Physiol 1987; 252 (4 Pt 1): E492-9
188. Brown MJ, Brown DC, Murphy MB. Hypokalemia from beta2-receptor stimulation by circulating epinephrine. N Engl J Med 1983; 309 (23): 1414-9
189. Di Giantomasso D, Bellomo R, May CN. The haemodynamic and metabolic effects of epinephrine in experimental hyperdynamic septic shock. Intensive Care Med 2005; 31 (3): 454-62
190. Reza MJ, Kovick RB, Shine KI, et al. Massive intravenous digoxin overdosage. N Engl J Med 1974; 291 (15): 777-8
191. Sterns RH, Cox M, Feig PU, et al. Internal potassium balance and the control of the plasma potassium concentration. Medicine (Baltimore) 1981 Sep; 60 (5): 339-54
192. Preston RA, Hirsh MJ, Oster MD Jr, et al. University of Miami Division of Clinical Pharmacology therapeutic rounds: drug-induced hyperkalemia. Am J Ther 1998 Mar: 5 (2): 125-32
193. Tuck M, Sambhi M, Levin L. Hyporeninemic hypoaldosteronism in diabetes mellitus. Diabetes 1979; 28: 237-41
194. Williams GH. Hyporeninemic hypoaldosteronism. N Engl J Med 1986; 314 (16): 1041-2
195. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf 2005; 28 (9): 763-88
196. Parfitt AM. Calcium homeostasis. In: Mundy GR, Martin JJ, editors. Physiology and phamacology of bone. Berlin: Springer-Verlag, 1993: 1-6
197. Brown EM, Hebert SC. Calcium-receptor-regulated parathyroid and renal function. Bone 1997 Apr; 20 (4): 303-9
198. Bohannon AD, Lyles KW. Drug-induced bone disease. Clin Geriatr Med 1994 Nov; 10 (4): 611-23
199. Bouillon R, Reynaert J, Claes JH, et al. The effect of anticonvulsant therapy on serum levels of 25-hydroxy-vitamin D, calcium, and parathyroid hormone. J Clin Endocrinol Metab 1975; 41 (6): 1130-5
200. Hahn TJ, Birge SJ, Scharp CR, et al. Phenobarbital-induced alterations in vitamin D metabolism. J Clin Invest 1972; 51 (4): 741-8
201. Devogelaer JP. Clinical use of bisphosphonates. Curr Opin Rheumatol 1996; 8 (4): 384-91
202. Peter R, Mishra V, Fraser WD. Severe hypocalcaemia after being given intravenous bisphosphonate. BMJ 2004; 328 (7435): 335-6
203. Henley D, Kaye J, Walsh J, et al. Symptomatic hypocalcaemia and renal impairment associated with bisphosphonate treatment in patients with multiple myeloma. Intern Med J 2005; 35 (12): 726-8
204. Rosen CJ, Brown S. Severe hypocalcemia after intravenous bisphosphonate therapy in occult vitamin D deficiency. N Engl J Med 2003; 348 (15): 1503-4
205. Hahn TJ, Hendin BA, Scharp CR, et al. Effect of chronic anticonvulsant therapy on serum 25-hydroxycalciferol levels in adults. N Engl J Med 1972; 287 (18): 900-4
206. Craig JC, Hodson EM, Martin HC. Phosphate enema poisoning in children. Med J Aust 1994; 160 (6): 347-51
207. Korzets A, Dicker D, Chaimoff C, et al. Life-threatening hyperphosphatemia and hypocalcemic tetany following the use of fleet enemas. J Am Geriatr Soc 1992; 40 (6): 620-1
208. Bolan CD, Cecco SA, Wesley RA, et al. Controlled study of citrate effects and response to i.v. calcium administration during allogeneic peripheral blood progenitor cell donation. Transfusion 2002; 42 (7): 935-46
209. Deaths associated with hypocalcemia from chelation therapy - Texas, Pennsylvania, and Oregon, 2003-2005. MMWR Morb Mortal Wkly Rep 2006; 55 (8): 204-7
210. Jacobson MA, Gambertoglio JG, Aweeka FT, et al. Foscarnet-induced hypocalcemia and effects of foscarnet on calcium metabolism. J Clin Endocrinol Metab 1991; 72 (5): 1130-5
211. Atsmon J, Dolev E. Drug-induced hypomagnesaemia: scope and management. Drug Saf 2005; 28 (9): 763-88
212. Lyman NW, Hemalatha C, Viscuso RL, et al. Cisplatin-induced hypocalcemia and hypomagnesemia. Arch Intern Med 1980; 140 (11): 1513-4
213. Barceloux DG, Krenzelok EP, Olson K, et al. American Academy of Clinical Toxicology Practice Guidelines on the Treatment of Ethylene Glycol Poisoning. Ad Hoc Committee. J Toxicol Clin Toxicol 1999; 37 (5): 537-60
214. Heath DA, Palmer JS, Aurbach GD. The hypocalcemic action of colchicine. Endocrinology 1972; 90 (6): 1589-93
215. Frayha RA, Tabbara Z, Berbir N. Acute colchicine poisoning presenting as symptomatic hypocalcaemia. Br J Rheumatol 1984; 23 (4): 292-5
216. Vinson DR, Burke TF, Sung HM. Rapid reversal of life-threatening diltiazem-induced tetany with calcium chloride. Ann Emerg Med 1999; 34 (5): 676-8
217. Bilezikian JP, Silverberg SJ. Clinical practice. Asymptomatic primary hyperparathyroidism. N Engl J Med 2004 Apr 22; 350 (17): 1746-51
218. Hoeck HC, Laurberg G, Laurberg P. Hypercalcaemic crisis after excessive topical use of a vitamin D derivative. J Intern Med 1994; 235 (3): 281-2
219. Ragavan VV, Smith JE, Bilezikian JP. Vitamin A toxicity and hypercalcemia. Am J Med Sci 1982; 283 (3): 161-4
220. Akiyama H, Nakamura N, Nagasaka S, et al. Hypercalcaemia due to all-trans retinoic acid. Lancet 1992; 339 (8788): 308-9
221. Picolos MK, Lavis VR, Orlander PR. Milk-alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) 2005; 63 (5): 566-76
222. Picolos MK, Orlander PR. Calcium carbonate toxicity: the updated milk-alkali syndrome; report of 3 cases and review of the literature. Endocr Pract 2005 Jul-Aug; 11 (4): 272-80
223. Spiegel AM, Rudorfer MV, Marx SJ, et al. The effect of short term lithium administration on suppressibility of parathyroid hormone secretion by calcium in vivo. J Clin Endocrinol Metab 1984; 59 (2): 354-7
224. Togari A. Adrenergic regulation of bone metabolism: possible involvement of sympathetic innervation of osteoblastic and osteoclastic cells. Microsc Res Tech 2002; 58 (2): 77-84
225. McPherson ML, Prince SR, Atamer ER, et al. Theophylline-induced hypercalcemia. Ann Intern Med 1986; 105 (1): 52-4
226. Bartalena L. Recent achievements in studies on thyroid hormone-binding proteins. Endocr Rev 1990 Feb; 11 (1): 47-64
227. Wolff J, Chaikoff I. Plasma inorganic iodide as homeostatic regulator of thyroid function. J Biol Chem 1948; 174: 555-64
228. Braverman LE, Ingbar SH. Changes in thyroidal function during adapation to large doses of iodide. J Clin Invest 1963; 42: 1216
229. Eng PH, Cardona GR, Fang SL, et al. Escape from the acute Wolff-Chaikoff effect is associated with a decrease in thyroid sodium/iodide symporter messenger ribonucleic acid and protein. Endocrinology 1999; 140 (8): 3404-10
230. Duncan L, Bateman DN. Sexual function in women: do antihypertensive drugs have an impact? Drug Saf 1993; 8 (3): 225-34
231. Cooper DS. Hyperthyroidism. Lancet 2003 Aug 9; 362 (9382): 459-68
232. Vorperian VR, Havighurst TC, Miller S, et al. Adverse effects of low dose amiodarone: a meta-analysis. J Am Coll Cardiol 1997; 30 (3): 791-8
233. Kennedy RL, Griffiths H, Gray TA. Amiodarone and the thyroid. Clin Chem 1989; 35 (9): 1882-7
234. Assessment of the iodine deficiency disorders and monitoring their elimination. A guide for programme managers. 2nd ed. Geneva: World Health Organization, 2001 (WHO/NHD/01.1)
235. Trifanescu R, Fica S, Barbu C, et al. Amiodarone-induced thyroid dysfunction in cardiac patients from areas with iodine deficiency. Rom J Intern Med 2004; 42 (3): 595-605
236. Basaria S, Cooper DS. Amiodarone and the thyroid. Am J Med 2005; 118 (7): 706-14
237. Dayan CM, Daniels GH. Chronic autoimmune thyroiditis. N Engl J Med 1996; 335 (2): 99-107
238. Rao RH, McCready VR, Spathis GS. Iodine kinetic studies during amiodarone treatment. J Clin Endocrinol Metab 1986; 62 (3): 563-8
239. Temple R, Berman M, Robbins J, et al. The use of lithium in the treatment of thyrotoxicosis. J Clin Invest 1972; 51 (10): 2746-56
240. Brownlie BE, Chambers ST, Sadler WA, et al. Lithium associated thyroid disease: a report of 14 cases of hypothyroidism and 4 cases of thyrotoxicosis. Aust N Z J Med 1976; 6 (3): 223-9
241. Spaulding SW, Burrow GN, Bermudez F, et al. The inhibitory effect of lithium on thyroid hormone release in both euthyroid and thyrotoxic patients. J Clin Endocrinol Metab 1972; 35 (6): 905-11
242. Lazarus JH. The effects of lithium therapy on thyroid and thyrotropin-releasing hormone. Thyroid 1998; 8 (10): 909-13
243. Bagchi N, Brown TR, Mack RE. Studies on the mechanism of inhibition of thyroid function by lithium. Biochim Biophys Acta 1978; 542 (1): 163-9
244. Chan WB, Chow CC, Cockram CS. A patient with low free T4 and low thyroid-stimulating hormone without hypopituitarism. Int J Clin Pract 2004; 58 (10): 983-4
245. Krotkiewski M. Thyroid hormones and treatment of obesity. Int J Obes Relat Metab Disord 2000; 24 Suppl. 2: S116-9
246. Chen WL. [Controversy in medical practice: the pros and cons of treating hyperthyroidism with iodine-containing Chinese traditional herb medicine (author's transl)]. Zhonghua Nei Ke Za Zhi 1980; 19 (5): 377-8
247. Preziati D, La Rosa L, Covini G, et al. Autoimmunity and thyroid function in patients with chronic active hepatitis treated with recombinant interferon alpha-2a. Eur J Endocrinol 1995; 132 (5): 587-93
248. Braga-Basaria M, Basaria S. Interferon-alpha-induced transient severe hypothyroidism in a patient with Graves' disease. J Endocrinol Invest 2003; 26 (3): 261-4
249. MacDonald PC, Madden JD, Brenner PF, et al. Origin of estrogen in normal men and in women with testicular feminization. J Clin Endocrinol Metab 1979; 49 (6): 905-16
250. Rampin O, Giuliano F. Central control of the cardiovascular and erection systems: possible mechanisms and interactions. Am J Cardiol 2000; 86 (2A): 19F-22F
251. Burnett AL, Musicki B. The nitric oxide signaling pathway in the penis. Curr Pharm Des 2005; 11 (31): 3987-94
252. Plosker GL, Brogden RN. Leuprorelin. A review of its pharmacology and therapeutic use in prostatic cancer, endometriosis and other sex hormone-related disorders. Drugs 1994; 48 (6): 930-67
253. MacAdams MR, White RH, Chipps BE. Reduction of serum testosterone levels during chronic glucocorticoid therapy. Ann Intern Med 1986; 104 (5): 648-51
254. Barradell LB, Faulds D. Cyproterone. A review of its pharmacology and therapeutic efficacy in prostate cancer. Drugs Aging 1994; 5 (1): 59-80
255. Barton C, Waxman J. Effects of chemotherapy on fertility. Blood Rev 1990; 4 (3): 187-95
256. Howell SJ, Shalet SM. Testicular function following chemotherapy. Hum Reprod Update 2001; 7 (4): 363-9
257. Molina JR, Barton DL, Loprinzi CL. Chemotherapy-induced ovarian failure: manifestations and management. Drug Saf 2005; 28 (5): 401-16
258. Whitten PL, Naftolin F. Reproductive actions of phytoestrogens. Baillieres Clin Endocrinol Metab 1998; 12 (4): 667-90
259. Solomon GM, Schettler T. Environment and health: 6. Endocrine disruption and potential human health implications. CMAJ 2000; 163 (11): 1471-6
260. Eertmans F, Dhooge W, Stuyvaert S, et al. Endocrine disruptors: effects on male fertility and screening tools for their assessment. Toxicol In Vitro 2003; 17 (5-6): 515-24
261. Turner KJ, Sharpe RM. Environmental oestrogens: present understanding. Rev Reprod 1997; 2 (2): 69-73
262. Landrigan P, Garg A, Droller DB. Assessing the effects of endocrine disruptors in the National Children's Study. Environ Health Perspect 2003; 111 (13): 1678-82
263. Merke DP, Bornstein SR. Congenital adrenal hyperplasia. Lancet 2005 Jun 18-24; 365 (9477): 2125-36
264. Lamb DR. Anabolic steroids in athletics: how well do they work and how dangerous are they? Am J Sports Med 1984; 12 (1): 31-8
265. Maravellas C, Dona A, Stefanidou M, et al. Adverse effects of anabolic steroids in athletes: a constant threat. Toxicol Lett 2005 Sep 15; 158 (3): 167-75
266. Church JA. Oxandrolone treatment of childhood hereditary angioedema. Ann Allergy Asthma Immunol 2004; 92 (3): 377-8
267. Kaltsas GA, Isidori AM, Besser GM, et al. Secondary forms of polycystic ovary syndrome. Trends Endocrinol Metab 2004; 15 (5): 204-10
268. Meo R, Bilo L. Polycystic ovary syndrome and epilepsy: a review of the evidence. Drugs 2003; 63 (12): 1185-227
269. Emiliano AB, Fudge JL. From galactorrhea to osteopenia: rethinking serotonin-prolactin interactions. Neuropsychopharmacology 2004 May; 29 (5): 833-46
270. Gitlin MJ. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J Clin Psychiatry 1994; 55 (9): 406-13
271. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004; 3 (5): 457-70
272. Dusing R. Sexual dysfunction in male patients with hypertension: influence of antihypertensive drugs. Drugs 2005; 65 (6): 773-86
273. Maggi M, Filippi S, Ledda F, et al. Erectile dysfunction: from biochemical pharmacology to advances in medical therapy. Eur J Endocrinol 2000; 143 (2): 143-54
274. Briganti A, Salonia A, Gallina A, et al. Emerging oral drugs for erectile dysfunction. Expert Opin Emerg Drugs 2004; 9 (1): 179-89
275. Nieman LK, Ilias I. Evaluation and treatment of Cushing's syndrome. Am J Med 2005 Dec; 118 (12): 1340-6
276. Turpeinen U, Markkanen H, Valimaki M, et al. Determination of urinary free cortisol by HPLC. Clin Chem 1997; 43 (8 Pt 1): 1386-91
277. Kudva YC, Sawka AM, Young WF, et al. Clinical review 164. The laboratory diagnosis of adrenal pheochromocytoma: the Mayo Clinic experience. J Clin Endocrinol Metab 2003; 88 (10): 4533-9
278. Wassell J, Reed P, Kane J, et al. Freedom from drug interference in new immunoassays for urinary catecholamines and metanephrines. Clin Chem 1999; 45 (12): 2216-23
279. Ma RC, Chan WB, So WY, et al. Carbamazepine and false positive dexamethasone suppression tests for Cushing's syndrome. BMJ 2005; 330 (7486): 299-300